Table 2. Multivariable analysis of selected demographic variables.
| Progression-free Survival | Overall Survival | ||||||
|---|---|---|---|---|---|---|---|
| Adjusted for Covariates | Adjusted for Covariates | ||||||
| HR | 95% CI | P | HR | 95% CI | P | ||
| Age | <65 | Ref | Ref | ||||
| ≥ 65 | 0.777 | 0.423 to 1.426 | 0.415 | 1.001 | 0.482 to 2.069 | 0.997 | |
| ECOG performance status | 0 | Ref | Ref | ||||
| ≥ 1 | 1.746 | 0.967 to 3.153 | 0.065 | 2.284 | 1.090 to 4.785 | 0.029 | |
| HER2 overexpression by IHC | 2+ | Ref | Ref | ||||
| 3+ | 0.529 | 0.282 to 0.993 | 0.048 | 1.092 | 0.486 to 2.453 | 0.832 | |
| ETS† | 0.858 | 0.765 to 0.961 | 0.008 | 0.869 | 0.758 to 0.996 | 0.044 | |
| Age | < 65 | Ref | Ref | ||||
| ≥ 65 | 0.796 | 0.441 to 1.436 | 0.448 | 1.119 | 0.536 to 2.335 | 0.764 | |
| ECOG performance status | 0 | Ref | Ref | ||||
| ≥ 1 | 1.415 | 0.775 to 2.582 | 0.258 | 1.876 | 0.868 to 4.055 | 0.110 | |
| HER2 overexpression by IHC | 2+ | Ref | Ref | ||||
| 3+ | 0.626 | 0.333 to 1.179 | 0.147 | 1.616 | 0.671 to 3.891 | 0.284 | |
| DpR† | 0.786 | 0.700 to 0.883 | < 0.0001 | 0.798 | 0.698 to 0.912 | 0.001 | |
†HR per 10% tumor size decrease
Abbreviations: HR, hazard ratio; CI, confidence interval; Ref, Reference; ECOG, Eastern Cooperative Oncology Group; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; ETS, early tumor shringkage; TTG, time to tumor growth; DpR, depth of response.